BR112013023599A2 - método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t - Google Patents
método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-tInfo
- Publication number
- BR112013023599A2 BR112013023599A2 BR112013023599-3A BR112013023599A BR112013023599A2 BR 112013023599 A2 BR112013023599 A2 BR 112013023599A2 BR 112013023599 A BR112013023599 A BR 112013023599A BR 112013023599 A2 BR112013023599 A2 BR 112013023599A2
- Authority
- BR
- Brazil
- Prior art keywords
- epitope conjugate
- cell carbohydrate
- carbohydrate
- cell
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Container Filling Or Packaging Operations (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11290138.4 | 2011-03-17 | ||
EP11290138A EP2500033A1 (en) | 2011-03-17 | 2011-03-17 | Method for preparing muliple antigen glycopeptide carbohydrate conjugates |
PCT/IB2012/051285 WO2012123926A1 (en) | 2011-03-17 | 2012-03-16 | Method for preparing multiple antigen glycopeptide carbohydrate conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013023599A2 true BR112013023599A2 (pt) | 2019-05-07 |
BR112013023599B1 BR112013023599B1 (pt) | 2023-01-10 |
Family
ID=44512239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013023599-3A BR112013023599B1 (pt) | 2011-03-17 | 2012-03-16 | Método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t |
Country Status (16)
Country | Link |
---|---|
US (2) | US20140378652A9 (pt) |
EP (2) | EP2500033A1 (pt) |
JP (1) | JP6006244B2 (pt) |
KR (1) | KR20140048107A (pt) |
CN (1) | CN103732246B (pt) |
AU (1) | AU2012227940A1 (pt) |
BR (1) | BR112013023599B1 (pt) |
CA (1) | CA2828688C (pt) |
DK (1) | DK2686009T3 (pt) |
EA (1) | EA201391202A1 (pt) |
ES (1) | ES2537180T3 (pt) |
IL (1) | IL228384A0 (pt) |
MX (1) | MX354325B (pt) |
SG (1) | SG193433A1 (pt) |
WO (1) | WO2012123926A1 (pt) |
ZA (1) | ZA201306219B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3410849B1 (en) | 2016-02-05 | 2023-07-05 | Institut Pasteur | Use of inhibitors of adam12 as adjuvants in tumor therapies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105503A (en) | 1992-04-28 | 1999-05-09 | Astra Ab | Carbon peptide couplets capable of eliciting an immune response of T cells |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US6676946B2 (en) * | 1997-03-27 | 2004-01-13 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
PT969873E (pt) | 1997-03-27 | 2006-09-29 | Pasteur Institut | Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso |
CA2286798C (en) * | 1997-04-16 | 2014-01-07 | Sloan-Kettering Institute For Cancer Research | Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof |
-
2011
- 2011-03-17 EP EP11290138A patent/EP2500033A1/en not_active Withdrawn
-
2012
- 2012-03-16 US US14/005,336 patent/US20140378652A9/en not_active Abandoned
- 2012-03-16 AU AU2012227940A patent/AU2012227940A1/en not_active Abandoned
- 2012-03-16 JP JP2013558565A patent/JP6006244B2/ja active Active
- 2012-03-16 EA EA201391202A patent/EA201391202A1/ru unknown
- 2012-03-16 BR BR112013023599-3A patent/BR112013023599B1/pt active IP Right Grant
- 2012-03-16 SG SG2013068762A patent/SG193433A1/en unknown
- 2012-03-16 EP EP20120712748 patent/EP2686009B1/en active Active
- 2012-03-16 CA CA2828688A patent/CA2828688C/en active Active
- 2012-03-16 MX MX2013010618A patent/MX354325B/es active IP Right Grant
- 2012-03-16 DK DK12712748.8T patent/DK2686009T3/da active
- 2012-03-16 KR KR1020137027111A patent/KR20140048107A/ko not_active Application Discontinuation
- 2012-03-16 CN CN201280011373.8A patent/CN103732246B/zh active Active
- 2012-03-16 WO PCT/IB2012/051285 patent/WO2012123926A1/en active Application Filing
- 2012-03-16 ES ES12712748.8T patent/ES2537180T3/es active Active
-
2013
- 2013-08-19 ZA ZA2013/06219A patent/ZA201306219B/en unknown
- 2013-09-12 IL IL228384A patent/IL228384A0/en unknown
-
2017
- 2017-02-28 US US15/444,547 patent/US10899799B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20140378652A9 (en) | 2014-12-25 |
WO2012123926A1 (en) | 2012-09-20 |
DK2686009T3 (da) | 2015-06-15 |
KR20140048107A (ko) | 2014-04-23 |
EP2500033A1 (en) | 2012-09-19 |
AU2012227940A1 (en) | 2013-09-05 |
EP2686009A1 (en) | 2014-01-22 |
SG193433A1 (en) | 2013-10-30 |
ZA201306219B (en) | 2014-05-28 |
US20170283466A1 (en) | 2017-10-05 |
CA2828688C (en) | 2021-08-03 |
ES2537180T3 (es) | 2015-06-03 |
IL228384A0 (en) | 2013-12-31 |
EP2686009B1 (en) | 2015-04-29 |
MX2013010618A (es) | 2014-04-14 |
JP6006244B2 (ja) | 2016-10-12 |
MX354325B (es) | 2018-02-26 |
JP2014510083A (ja) | 2014-04-24 |
BR112013023599B1 (pt) | 2023-01-10 |
EA201391202A1 (ru) | 2014-03-31 |
CA2828688A1 (en) | 2012-09-20 |
CN103732246A (zh) | 2014-04-16 |
US20140171618A1 (en) | 2014-06-19 |
CN103732246B (zh) | 2017-06-30 |
US10899799B2 (en) | 2021-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP14004976A (es) | Anticuerpos anti-il-36r | |
PH12015500243B1 (en) | Glycoconjugation processes and compositions | |
EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
MY170719A (en) | Antibody-drug conjugates | |
GT201300046A (es) | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
ECSP13012649A (es) | Anticuerpos ANTI-IL-23 | |
MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
EA201490095A1 (ru) | Новые производные майтанзиноида с пептидным линкером и их конъюгаты | |
BR112013031493A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto. | |
CO6450612A2 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
CO7200270A2 (es) | Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas | |
EA201491195A1 (ru) | Способ получения композиции, содержащей галактоолигосахариды | |
BR112015000188A2 (pt) | isolados de proteína de batata | |
BR112015004515A2 (pt) | composição imunogênica | |
CY1118539T1 (el) | Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο | |
BR112015008824A2 (pt) | linhagens melhoradas de microalgas e processo das mesmas | |
BR112012009310A2 (pt) | composto, e, composição farmacêutica | |
MX362371B (es) | Proceso para preparar 2-metoximetil-1,4-bencenodiamina y sales de esta. | |
GB2495884A (en) | A method of increasing the effect of an activated-potentiated form of an antibody | |
DOP2015000007A (es) | Métodos para preparar triazolopiridinas sutituidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: INSTITUT PASTEUR (FR) ; CENTRE NATIONAL DE LA RECH |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/03/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |